• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Intertriginous erythema associated with enfortumab vedotin, a nectin-4-targeting antibody-drug conjugate, in a case with metastatic urothelial cancer: Immunohistochemical evidence for molecular-targeted eruption.

作者信息

Hasegawa Takumi, Oyama Noritaka, Kasamatsu Hiroshi, Chino Takenao, Taga Minekatsu, Hasegawa Minoru

机构信息

Department of Dermatology, Division of Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.

Department of Urology, Division of Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.

出版信息

J Dermatol. 2022 Dec;49(12):e453-e454. doi: 10.1111/1346-8138.16567. Epub 2022 Sep 2.

DOI:10.1111/1346-8138.16567
PMID:36052729
Abstract
摘要

相似文献

1
Intertriginous erythema associated with enfortumab vedotin, a nectin-4-targeting antibody-drug conjugate, in a case with metastatic urothelial cancer: Immunohistochemical evidence for molecular-targeted eruption.恩扎妥昔单抗（一种靶向Nectin-4的抗体药物偶联物）相关的擦烂性红斑在一例转移性尿路上皮癌患者中的病例报告：分子靶向性皮疹的免疫组织化学证据
J Dermatol. 2022 Dec;49(12):e453-e454. doi: 10.1111/1346-8138.16567. Epub 2022 Sep 2.
2
[Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma].[抗NECTIN-4抗体药物偶联物作为转移性尿路上皮癌患者的一种新治疗选择]
Urologie. 2023 Nov;62(11):1193-1199. doi: 10.1007/s00120-023-02175-5. Epub 2023 Sep 1.
3
Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.抗体药物偶联物靶向 nectin-4 治疗尿路上皮癌。
Expert Opin Biol Ther. 2021 Jul;21(7):863-873. doi: 10.1080/14712598.2021.1929168. Epub 2021 May 24.
4
Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.恩福妥单抗（enfortumab vedotin-ejfv）治疗晚期尿路上皮癌。
Expert Rev Anticancer Ther. 2022 May;22(5):449-455. doi: 10.1080/14737140.2022.2069563. Epub 2022 Apr 26.
5
Is HER2 the New NECTIN4 in Advanced Urothelial Cancer?HER2会成为晚期尿路上皮癌中新型NECTIN4吗？
Eur Urol Focus. 2024 Mar;10(2):219-221. doi: 10.1016/j.euf.2024.05.018. Epub 2024 Jun 1.
6
The emerging role of antibody-drug conjugates in urothelial carcinoma.抗体偶联药物在膀胱癌中的新兴作用。
Expert Rev Anticancer Ther. 2020 Jul;20(7):551-561. doi: 10.1080/14737140.2020.1782201. Epub 2020 Jul 21.
7
Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.与恩福妥滨单抗相关的皮肤毒性的临床和直接免疫荧光特征。
Br J Dermatol. 2022 Jul;187(1):126-127. doi: 10.1111/bjd.21022. Epub 2022 Apr 19.
8
Biomarkers of Response to Anti-NECTIN4 Antibody-Drug Conjugate Enfortumab Vedotin in Urothelial Cancer.尿路上皮癌中抗NECTIN4抗体药物偶联物恩诺单抗反应的生物标志物
Eur Urol Focus. 2024 Mar;10(2):224-226. doi: 10.1016/j.euf.2024.04.001. Epub 2024 Apr 16.
9
Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance.抓表面现象：NECTIN-4 可作为恩福妥滨单抗耐药的替代标志物。
Clin Cancer Res. 2023 Apr 14;29(8):1377-1380. doi: 10.1158/1078-0432.CCR-22-3882.
10
The biology and rationale of targeting nectin-4 in urothelial carcinoma.靶向尿路上皮癌中 nectin-4 的生物学和原理。
Nat Rev Urol. 2021 Feb;18(2):93-103. doi: 10.1038/s41585-020-00394-5. Epub 2020 Nov 25.